Bellicum Pharma (BLCM) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Bellicum Pharma (BLCM) Misses Q2 EPS by 5c
August 7, 2018 4:05 PM EDT
HOUSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the second quarter ended June 30, 2018, and provided an update on recent developments.
We made substantial progress during the second quarter, with key data readouts expected later in 2018, said Bellicums President & CEO Rick Fair. Registration studies with our polyclonal allogeneic cell therapy, BPX-501, are on track and we expect to file MAAs in the European Union in 2019. In anticipation of these filings, we have... More
